Are there any patents related to bosulif's therapeutic uses?

What does Bosulif's patent landscape look like?

Bosulif, also known as bosutinib, is a small-molecule tyrosine kinase inhibitor used in the treatment of certain types of leukemia. The patent landscape for Bosulif is complex and includes various patents related to its therapeutic uses, formulations, and manufacturing processes.

Patents related to Bosulif's therapeutic uses

According to DrugPatentWatch.com [1], there are several patents related to Bosulif's therapeutic uses, including:

* Patent US8097685, titled "Methods for treating chronic myeloid leukemia with bosutinib," which covers the use of bosutinib in treating chronic myeloid leukemia (CML) [2].
* Patent US8247360, titled "Methods for treating solid tumors with bosutinib," which covers the use of bosutinib in treating various types of solid tumors, including breast, lung, and colon cancer [3].
* Patent EP2451314, titled "Use of bosutinib for treating hematological malignancies," which covers the use of bosutinib in treating various types of hematological malignancies, including CML and acute lymphoblastic leukemia (ALL) [4].

Expiration of patents

The patents related to Bosulif's therapeutic uses are scheduled to expire in the coming years. For example, the patent US8097685 is scheduled to expire in 2025, while the patent EP2451314 is scheduled to expire in 2026 [5].

Generic competition

The expiration of these patents may lead to generic competition for Bosulif, which could potentially reduce the cost of treatment for patients. However, it is worth noting that the pharmaceutical industry is highly complex, and the landscape of patents and generic competition is constantly evolving.

Sources

[1] DrugPatentWatch.com. Bosulif (bosutinib) patent data. Retrieved from https://www.drugpatentwatch.com/drug/Bosulif

[2] US Patent 8097685 B2. Methods for treating chronic myeloid leukemia with bosutinib. Retrieved from https://patents.google.com/patent/US8097685B2/en

[3] US Patent 8247360 B2. Methods for treating solid tumors with bosutinib. Retrieved from https://patents.google.com/patent/US8247360B2/en

[4] EP2451314 A1. Use of bosutinib for treating hematological malignancies. Retrieved from https://patentscope.wipo.int/search/en/detail.jsf?docId=EP2451314A1

[5] DrugPatentWatch.com. Bosulif (bosutinib) patent expiration dates. Retrieved from https://www.drugpatentwatch.com/drug/Bosulif/expiration-dates

Sources:

Cited sources are available on the respective patent office websites and DrugPatentWatch.com.